<DOC>
	<DOCNO>NCT01332890</DOCNO>
	<brief_summary>To evaluate drug-drug interaction</brief_summary>
	<brief_title>Pharmacokinetic Drug Interaction Between Revaprazan Itopride HCl Healthy Male Subjects</brief_title>
	<detailed_description>The main objective evaluate pharmacokinetic profile 50mg Revaprazan plus 50mg Itopride compare 50mg Revaprazan 50mg Itopride alone healthy Korean subject</detailed_description>
	<criteria>Males age 20 50 year old , body mass index ( BMI ) 19 27 kg/m2 Acceptable medical history , physical exam , laboratory test EKG , screen Eligible blood sample study period Provision sign write informed consent History clinically significant disease History drug/chemical/alcohol abuse Clinically significant illness within 30days first dose Use medication know chronically alter drug absorption elimination process within 30days first dose investigational product Use prescribe medication 14 day administration first dose investigational product Use nonprescribed medication 7 day administration first dose investigational product Use oriental medication medication 30 day administration first dose investigational product Participated clinical study involve administration investigational drug ( new chemical entity ) market drug within past 90 day Consuming 21 unit alcohol per week Smoking 20 cigarette per day consume 5 cup caffeinated beverage .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Drug interaction</keyword>
	<keyword>revaprazan</keyword>
	<keyword>Itopride HCI</keyword>
</DOC>